Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Youssef

Showing results (11-20 of 41) with videos related to

Pageof 5
Sort By:
Emergency Medicine Australasia : EMA|April 13, 2026
Pathology Testing for Patients With Low Back Pain in Australian Emergency DepartmentsClaudia Côté-Picard, Qiuzhe Chen, Hugo Massé-Alarie, et al.
Internal Medicine Journal|June 1, 2017
Outcomes of pulmonary arterial hypertension therapy in Australia: is monotherapy adequate?Avalon Moonen, Roger Garsia, Peter Youssef, et al.
International Journal of Rheumatic Diseases|October 18, 2013
A retrospective chart review of the use of rituximab for the treatment of rheumatoid arthritis in Australian rheumatology practiceDave Nicholls, Jane Zochling, Anthony Boers, et al.
The Journal of Rheumatology|December 3, 2019
Reasons for Biologic and Targeted Synthetic Disease-modifying Antirheumatic Drug Cessation and Persistence of Second-line Treatment in a Rheumatoid Arthritis DatasetPeter Youssef, Bruno Marcal, Peter Button, et al.
Frontiers in Pain Research (Lausanne, Switzerland)|October 10, 2025
Expectations about pain management after discharge from total hip and knee replacement surgery: a qualitative study with patients and prescribersIan Liang, Peter Youssef, Abby Haynes, et al.
Journal of Clinical Medicine|May 5, 2017
Role of Autoantibodies in the Diagnosis of Connective-Tissue Disease ILD (CTD-ILD) and Interstitial Pneumonia with Autoimmune Features (IPAF)Adelle S Jee, Stephen Adelstein, Jane Bleasel, et al.
Rheumatology and Therapy|January 5, 2025
Real-World Persistence and Effectiveness of Upadacitinib versus Other Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Australian Patients with Rheumatoid ArthritisPeter Youssef, Sabina Ciciriello, Talib Tahir, et al.
Clinical Rheumatology|March 8, 2024
Real-world evaluation of persistence, effectiveness and usage patterns of tofacitinib in treatment of psoriatic arthritis in AustraliaGeoffrey Littlejohn, Joanna Leadbetter, Belinda E Butcher, et al.
Connective Tissue Research|October 5, 2011
Not all lubricin isoforms are substituted with a glycosaminoglycan chainMegan S Lord, Ruby P Estrella, Christine Y Chuang, et al.
ACR Open Rheumatology|June 12, 2023
Comparative Effectiveness of First-Line Baricitinib in Patients With Rheumatoid Arthritis in the Australian OPAL Data SetSabina Ciciriello, Geoffrey Littlejohn, Tamas Treuer, et al.
Pageof 5

Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
Emergency Medicine Australasia : EMA|April 13, 2026
Pathology Testing for Patients With Low Back Pain in Australian Emergency DepartmentsClaudia Côté-Picard, Qiuzhe Chen, Hugo Massé-Alarie, et al.
Internal Medicine Journal|June 1, 2017
Outcomes of pulmonary arterial hypertension therapy in Australia: is monotherapy adequate?Avalon Moonen, Roger Garsia, Peter Youssef, et al.
International Journal of Rheumatic Diseases|October 18, 2013
A retrospective chart review of the use of rituximab for the treatment of rheumatoid arthritis in Australian rheumatology practiceDave Nicholls, Jane Zochling, Anthony Boers, et al.
The Journal of Rheumatology|December 3, 2019
Reasons for Biologic and Targeted Synthetic Disease-modifying Antirheumatic Drug Cessation and Persistence of Second-line Treatment in a Rheumatoid Arthritis DatasetPeter Youssef, Bruno Marcal, Peter Button, et al.
Frontiers in Pain Research (Lausanne, Switzerland)|October 10, 2025
Expectations about pain management after discharge from total hip and knee replacement surgery: a qualitative study with patients and prescribersIan Liang, Peter Youssef, Abby Haynes, et al.
Journal of Clinical Medicine|May 5, 2017
Role of Autoantibodies in the Diagnosis of Connective-Tissue Disease ILD (CTD-ILD) and Interstitial Pneumonia with Autoimmune Features (IPAF)Adelle S Jee, Stephen Adelstein, Jane Bleasel, et al.
Rheumatology and Therapy|January 5, 2025
Real-World Persistence and Effectiveness of Upadacitinib versus Other Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Australian Patients with Rheumatoid ArthritisPeter Youssef, Sabina Ciciriello, Talib Tahir, et al.
Clinical Rheumatology|March 8, 2024
Real-world evaluation of persistence, effectiveness and usage patterns of tofacitinib in treatment of psoriatic arthritis in AustraliaGeoffrey Littlejohn, Joanna Leadbetter, Belinda E Butcher, et al.
Connective Tissue Research|October 5, 2011
Not all lubricin isoforms are substituted with a glycosaminoglycan chainMegan S Lord, Ruby P Estrella, Christine Y Chuang, et al.
ACR Open Rheumatology|June 12, 2023
Comparative Effectiveness of First-Line Baricitinib in Patients With Rheumatoid Arthritis in the Australian OPAL Data SetSabina Ciciriello, Geoffrey Littlejohn, Tamas Treuer, et al.
Pageof 5